Related Experiment Videos
Clinical evaluation of piperacillin in bronchopulmonary infection
Abstract:
Piperacillin sodium, a new semi-synthetic penicillin, was administered to eleven patients with acute bronchial infection and to fourteen patients with pneumonia. Piperacillin dosage was either 8 g/day (twenty-one patients) or 16 g/day (four patients) intravenously for periods of between 5 and 15 days. Clinical assessment was determined by diminution of sputum purulence, eradication of pathogen from sputum, clinical and radiological progress. There was a beneficial response in all but six patients, two of whom had severe chronic infective bronchial disease and four had underlying pulmonary malignancy. The low toxicity of piperacillin was confirmed, although one patient with chronic renal failure had a significant decline in renal function. Dosage should be reduced in patients with renal impairment.
Insights
Piperacillin sodium effectively treated acute bronchial infections and pneumonia in most patients. Researchers confirmed piperacillin
Area of Science:
- Pharmacology
- Infectious Diseases
- Respiratory Medicine
Background:
- Piperacillin sodium is a novel semi-synthetic penicillin antibiotic.
- Bacterial respiratory tract infections necessitate effective antimicrobial therapies.
Purpose of the Study:
- To evaluate the efficacy and safety of piperacillin sodium in treating patients with acute bronchial infections and pneumonia.
Main Methods:
- Eleven patients with acute bronchial infection and fourteen with pneumonia received intravenous piperacillin sodium.
- Dosages administered were 8 g/day or 16 g/day for 5 to 15 days.
- Clinical assessment included sputum purulence, pathogen eradication, and clinical/radiological progress.
Main Results:
- A beneficial response was observed in all patients except six, primarily those with severe chronic lung disease or malignancy.
- Piperacillin sodium demonstrated low toxicity.
- One patient with chronic renal failure experienced a decline in renal function, indicating a need for dosage adjustment.
Conclusions:
- Piperacillin sodium is an effective treatment for bacterial respiratory infections like pneumonia and bronchial infections.
- Dosage reduction is recommended for patients with renal impairment to mitigate potential adverse effects.